CN115215764A - Preparation method of deuterated aromatic nitrile compound - Google Patents
Preparation method of deuterated aromatic nitrile compound Download PDFInfo
- Publication number
- CN115215764A CN115215764A CN202210812275.XA CN202210812275A CN115215764A CN 115215764 A CN115215764 A CN 115215764A CN 202210812275 A CN202210812275 A CN 202210812275A CN 115215764 A CN115215764 A CN 115215764A
- Authority
- CN
- China
- Prior art keywords
- deuterated
- aromatic nitrile
- compound
- sodium
- nitrile compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 deuterated aromatic nitrile compound Chemical class 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000003054 catalyst Substances 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 13
- 229910052805 deuterium Inorganic materials 0.000 claims abstract description 12
- 229910052751 metal Inorganic materials 0.000 claims abstract description 12
- 239000002184 metal Substances 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 12
- 239000012752 auxiliary agent Substances 0.000 claims abstract description 11
- 239000007800 oxidant agent Substances 0.000 claims abstract description 11
- 238000011065 in-situ storage Methods 0.000 claims abstract description 10
- 239000012298 atmosphere Substances 0.000 claims abstract description 9
- 230000003197 catalytic effect Effects 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 230000001590 oxidative effect Effects 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 claims description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- UHOVQNZJYSORNB-MZWXYZOWSA-N benzene-d6 Chemical compound [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H] UHOVQNZJYSORNB-MZWXYZOWSA-N 0.000 claims description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 5
- 239000005708 Sodium hypochlorite Substances 0.000 claims description 5
- 239000001632 sodium acetate Substances 0.000 claims description 5
- 235000017281 sodium acetate Nutrition 0.000 claims description 5
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000005002 aryl methyl group Chemical group 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- JHWIEAWILPSRMU-UHFFFAOYSA-N 2-methyl-3-pyrimidin-4-ylpropanoic acid Chemical compound OC(=O)C(C)CC1=CC=NC=N1 JHWIEAWILPSRMU-UHFFFAOYSA-N 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
- 229910021503 Cobalt(II) hydroxide Inorganic materials 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 229910052786 argon Inorganic materials 0.000 claims description 3
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- ASKVAEGIVYSGNY-UHFFFAOYSA-L cobalt(ii) hydroxide Chemical compound [OH-].[OH-].[Co+2] ASKVAEGIVYSGNY-UHFFFAOYSA-L 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims description 3
- 239000007789 gas Substances 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 229910052748 manganese Inorganic materials 0.000 claims description 3
- 239000011572 manganese Substances 0.000 claims description 3
- 229940071125 manganese acetate Drugs 0.000 claims description 3
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- UCFFGYASXIPWPD-UHFFFAOYSA-N methyl hypochlorite Chemical compound COCl UCFFGYASXIPWPD-UHFFFAOYSA-N 0.000 claims description 3
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 235000011056 potassium acetate Nutrition 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 claims description 3
- 229940039790 sodium oxalate Drugs 0.000 claims description 3
- 229960001922 sodium perborate Drugs 0.000 claims description 3
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 claims description 3
- 229930192474 thiophene Natural products 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- 239000011261 inert gas Substances 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 3
- 229960005101 febuxostat Drugs 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical class C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- MNNDREXLRLDWEY-UHFFFAOYSA-N 2-bromo-4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C(Br)=C1 MNNDREXLRLDWEY-UHFFFAOYSA-N 0.000 description 2
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 2
- UYHCIOZMFCLUDP-UHFFFAOYSA-N 4-phenoxybenzonitrile Chemical compound C1=CC(C#N)=CC=C1OC1=CC=CC=C1 UYHCIOZMFCLUDP-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- RJYMRRJVDRJMJW-UHFFFAOYSA-L dibromomanganese Chemical compound Br[Mn]Br RJYMRRJVDRJMJW-UHFFFAOYSA-L 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical compound NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- KTDRJLRJAHBQDQ-UHFFFAOYSA-N 4-amino-2-methoxybenzonitrile Chemical compound COC1=CC(N)=CC=C1C#N KTDRJLRJAHBQDQ-UHFFFAOYSA-N 0.000 description 1
- UNVOVHZEERXLPY-UHFFFAOYSA-N 4-methoxy-3-phenoxybenzonitrile Chemical compound COC1=CC=C(C#N)C=C1OC1=CC=CC=C1 UNVOVHZEERXLPY-UHFFFAOYSA-N 0.000 description 1
- ZSCUWVQXQDCSRV-UHFFFAOYSA-N 4-morpholin-4-ylbenzonitrile Chemical compound C1=CC(C#N)=CC=C1N1CCOCC1 ZSCUWVQXQDCSRV-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 238000010499 C–H functionalization reaction Methods 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- LEZYOCCNZPWBBZ-UHFFFAOYSA-M [Br-].C(=O)=[Mn+] Chemical compound [Br-].C(=O)=[Mn+] LEZYOCCNZPWBBZ-UHFFFAOYSA-M 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960002049 etravirine Drugs 0.000 description 1
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- PRMWGUBFXWROHD-UHFFFAOYSA-N perampanel Chemical compound O=C1C(C=2C(=CC=CC=2)C#N)=CC(C=2N=CC=CC=2)=CN1C1=CC=CC=C1 PRMWGUBFXWROHD-UHFFFAOYSA-N 0.000 description 1
- 229960005198 perampanel Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- XQZYPMVTSDWCCE-UHFFFAOYSA-N phthalonitrile Chemical compound N#CC1=CC=CC=C1C#N XQZYPMVTSDWCCE-UHFFFAOYSA-N 0.000 description 1
- 229920006391 phthalonitrile polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention discloses a preparation method of a deuterated aromatic nitrile compound, which is characterized in that the aromatic nitrile compound shown in formula (I) is used as a raw material, under the protection of inert atmosphere, the aromatic nitrile compound and an aliphatic alcohol compound generate aryl formimidate in situ in a catalytic system, then the aryl formimidate and a deuterated reagent generate hydrogen-deuterium exchange reaction, the aryl formimidate and the deuterated reagent are hydrolyzed in situ to obtain an aromatic nitrile ortho-position deuterated compound, and finally the product is separated and purified; the catalytic system comprises a metal catalyst, an auxiliary agent, an oxidant and a solvent. The method has the advantages of high operability and good deuteration effect.
Description
Technical Field
The invention relates to the technical field of synthesis of deuterated compounds, in particular to a preparation method of deuterated aromatic nitrile compounds.
Background
Deuterium is a stable form of nonradioactive isotope of hydrogen in nature, with carbon-deuterium bonds being more stable (6-9 times) than carbon-hydrogen bonds due to its greater atomic mass than hydrogen. In recent years, with the research on deuterated compounds, the research shows that after hydrogen in drug molecules is replaced by deuterium, metabolic sites can be sealed, and the generation of toxic metabolites can be reduced. In addition, deuteration can slow the rate of systemic clearance and thus prolong the half-life of the drug in vivo. Therefore, the aim of reducing the toxic and side effects of the drug can be achieved by reducing the single administration dosage without affecting the pharmacological activity of the drug. Due to the special pharmacokinetic properties of deuterated drugs, the research and development speed of deuterated drugs is accelerated in recent years, and the demand for various active compound deuteration strategies is increasing.
The cyano group has good biocompatibility and can often penetrate deep into the target protein to form hydrogen bond interaction with key amino acid residues of an active site; meanwhile, the cyano can also be used as a metabolic blocking site to inhibit small molecules from oxidative metabolism and improve the metabolic stability of the compound in vivo. As an important organic drug group, aromatic nitrile and its derivatives have wide application in the aspects of medicine and the like.
For example, verapamil is a calcium channel blocker and is used for treating diseases such as hypertension, angina, arrhythmia, cerebrovascular diseases and the like; febuxostat has obvious inhibiting effect on the XOR of the oxidized form and the reduced form, so that the effect of reducing uric acid is stronger and more durable, and the febuxostat can be used for treating chronic hyperuricemia caused by gout; etravirine is a new generation of non-nucleoside reverse transcriptase inhibitor, and can greatly reduce the morbidity and mortality of AIDS; perampanel is commonly used for the additive treatment of adults and children with partial epileptic seizures (with or without secondary generalized seizures) aged 12 years and older; 2- (4-substituted piperazine-1-yl) methylbenzonitrile serving as an antitumor drug has a stronger inhibition rate on tumor strains Skov3 (human ovarian cancer) than on other tumor strains; bicalutamide is used for the treatment of advanced prostate cancer.
At present, the research on deuteration on aromatic rings of aromatic nitrile derivatives is still in the initial stage. Because the carbon-nitrogen triple bond of the nitrile is a linear structure, and the catalyst is difficult to form a cyclic metal transition state with a nitrogen atom and an ortho-position hydrogen atom on an aromatic ring for catalytic reaction, the method has a great challenge for the aromatic nitrile compound ring whether in C-H activation or H/D exchange reaction. In addition, cyano is a reactive functional group in organic synthesis, can be converted into other functional groups or heterocycles, and has low tolerance to reaction conditions.
At present, few reports are made on the preparation method of the deuterated aromatic nitrile derivative. In 2014, dieter Muri et al indirectly obtain a deuterated aromatic nitrile product through a deuterated amide compound by using an iridium metal complex. Deuterium is used as a deuterium source in the reaction, and the catalyst is complex in structure and expensive in price, so that the application range of the catalyst is greatly limited;
disclosure of Invention
The invention aims to provide a preparation method of a deuterated aromatic nitrile compound, which has the advantages of high operability and good deuterated effect.
The technical scheme adopted by the invention for solving the technical problems is as follows:
a preparation method of deuterated aromatic nitrile compounds comprises the steps of taking aromatic nitrile compounds shown in formula (I) as raw materials, generating aryl methyl imidic ester in situ with aliphatic alcohol compounds in a catalytic system under the protection of inert atmosphere, then generating hydrogen-deuterium exchange reaction with deuterated reagents, then hydrolyzing in situ to obtain deuterated compounds at ortho positions of the aromatic nitrile, and finally separating and purifying products; the catalytic system comprises a metal catalyst, an auxiliary agent, an oxidant and a solvent;
the invention uses cheap metal as catalyst, uses one-pot two-step method, and has simple operation and high exchange degree of hydrogen and deuterium without separating intermediate. The method has the characteristics of good operability and stability, high catalytic efficiency, high economic benefit, simple and convenient operation, easy separation of products and the like.
Preferably, the deuterated reagent is one of deuterium oxide, deuterated methanol and deuterated benzene. More preferably heavy water.
Preferably, the inert gas atmosphere is a gas atmosphere composed of nitrogen or argon.
Preferably, the metal catalyst is selected from one of decacarbonyl manganese, pentacarbonyl manganese bromide, manganese acetate, cobalt hydroxide, ferric oxide and ferroferric oxide. When manganese pentacarbonyl bromide is selected, the highest deuteration degree can reach 98%.
Preferably, the auxiliary agent is one of sodium acetate, potassium acetate, sodium oxalate, sodium carbonate and potassium carbonate. When sodium acetate is selected, the highest deuteration degree can reach 95%. The addition of the auxiliary agent can effectively promote the exchange rate of hydrogen and deuterium in the reaction process and improve the reaction deuteration degree.
Preferably, the solvent is one of N-methylpyrrolidone, tetrahydrofuran, dioxane, cyclohexane and cyclopentyl methyl ether. N-methyl pyrrolidone is preferred, and when the solvent is selected, the highest deuteration degree of the product can reach 95%.
Preferably, the oxidizing agent is one of sodium hypochlorite, hydrogen peroxide, peracetic acid, sodium dichromate, sodium perborate, potassium perborate, and methyl hypochlorite. When sodium hypochlorite is selected, the highest deuteration degree can reach 95%. The addition of the oxidizing agent can promote the in-situ generation of the aryl formimidate by the nitrile compound and the alcohol.
Preferably, the aliphatic alcohol compound is one of methanol, ethanol, isopropanol, tert-butanol and benzyl alcohol. When ethanol is selected, the highest deuteration degree can reach 98 percent.
Preferably, the molar ratio of the materials is aromatic nitrile compounds: fatty alcohol compounds: oxidizing agent: a deuterated reagent: metal catalyst: auxiliary agent: solvent =1:1.1:1:10-500:0.05-0.20:1:20-500.
Preferably, R is 1 Is one or more of alkyl, alkoxy, vinyl, aromatic substituent, nitro, amino, trifluoromethyl, halogen, pyridine, thiophene and furan; the R is 2 Is one or more of benzyl, methyl, ethyl, isopropyl, tertiary butyl, alkoxy, allyl and tertiary butyl. The alkyl group can be selected from saturated hydrocarbon with 1-6 carbon atoms, cyclopropyl, cyclobutyl, cyclopentyl, cyclobutyl, etc. The aromatic substituent may be phenyl, naphthalene, etc.
The invention has the beneficial effects that: the method utilizes the transition metal to activate the aromatic nitrile compound, realizes the deuteration reaction of the aromatic nitrile compound by forming the intermediate of aryl formimidate and taking the deuteration reagent as a deuterium source, realizes the synthesis of a deuteration product, and has the advantages of high operability, convenient operation and low cost.
The method is completed by adopting a technical route under the conventional laboratory conditions, the solvent is not required to be replaced midway in the one-pot reaction, and the method has the advantages of high reaction operability, good deuteration effect, good selectivity and wide application range.
The process method has good universality, can be used for preparing various deuterated aromatic nitrile compounds, and is also suitable for various aromatic nitrile medicaments.
Detailed Description
The technical solution of the present invention will be further specifically described below by way of specific examples.
In the present invention, the raw materials and equipment used are commercially available or commonly used in the art, unless otherwise specified. The methods in the following examples are conventional in the art unless otherwise specified.
General description of the embodiments
A preparation method of deuterated aromatic nitrile compounds comprises the steps of taking aromatic nitrile compounds shown in formula (I) as raw materials, under the protection of inert atmosphere, firstly generating aryl formimidate in situ with aliphatic alcohol compounds in a catalytic system, then generating hydrogen-deuterium exchange reaction with deuterated reagents, then performing in situ hydrolysis to obtain aromatic nitrile ortho-position deuterated compounds, and finally separating and purifying products; the catalytic system comprises a metal catalyst, an auxiliary agent, an oxidant and a solvent;
the deuterated reagent is one of heavy water, deuterated methanol and deuterated benzene; the inert atmosphere is a gas environment consisting of nitrogen or argon; the metal catalyst is selected from one of decacarbonyl manganese, pentacarbonyl manganese bromide, manganese acetate, cobalt hydroxide, ferric oxide and ferroferric oxide; the auxiliary agent is one of sodium acetate, potassium acetate, sodium oxalate, sodium carbonate and potassium carbonate; the solvent is one of N-methyl pyrrolidone, tetrahydrofuran, dioxane, cyclohexane and cyclopentyl methyl ether; the oxidant is one of sodium hypochlorite, hydrogen peroxide, peracetic acid, sodium dichromate, sodium perborate, potassium perborate and methyl hypochlorite; the aliphatic alcohol compound is one of methanol, ethanol, isopropanol, tert-butanol and benzyl alcohol.
The molar ratio of the materials is aromatic nitrile compounds: fatty alcohol compounds: oxidizing agent: a deuterated reagent: metal catalyst: auxiliary agent: solvent =1:1.1:1:10-500:0.05-0.20:1:20-500.
The R is 1 Is one or more of alkyl, alkoxy, vinyl, aromatic substituent, nitro, amino, trifluoromethyl, halogen, pyridine, thiophene and furan; said R is 2 Is one or more of benzyl, methyl, ethyl, isopropyl, tertiary butyl, alkoxy, allyl and tertiary butyl.
Example 1 synthesis of phthalonitrile ortho-deuterated product:
taking 15mL of dry sealed tube under nitrogen atmosphere, according toBenzonitrile (103mg, 1mmol) and sodium hypochlorite (150mg, 2mmol) were added in portions, ethanol (0.1 mL) was slowly added dropwise with stirring, and the reaction solution was reacted at room temperature for 24 hours (in situ preparation of arylformimidate). To the reaction mixture was then added carbonyl manganese bromide (27.5mg, 0.1mmol), sodium acetate (82mg, 1mmol), N-methylpyrrolidone: heavy water =0.5/0.5mL (v/v = 1/1), and reacted at 100 ℃ for 0.5 hour. After the reaction was completed, 5mL1N aq HCl was added, and the mixture was stirred at room temperature for about 1 hour (arylformimidate was hydrolyzed to obtain aromatic nitrile). Extraction was 2-3 times with 10mL ethyl acetate, the organic phase was dried and concentrated to give the crude product. And purifying the crude product by column chromatography to obtain a benzonitrile ortho-deuterated product. 1 H NMR(500MHz,Chloroform-d)δ7.62(m,1H),7.60-7.54(m,0.2H),7.49-7.47(m,2H)。
Under the same conditions, starting from the respective substituted aromatic nitrile derivatives, derivative 1 (deuterated aromatic nitrile derivative represented by formula II) was obtained under the conditions described above, the results of which are shown in the following table:
aromatic nitrile compound raw material | Deuterated products | Degree of deuteration (%) | Yield (%) | |
Example 2 | 4-aminophenylacetonitrile | 2-d | 91 | 63 |
Example 3 | 4-fluorobenzonitrile | 3-d | 90 | 64 |
Example 4 | 3, 5-difluorobenzonitrile | 4-d | 89 | 69 |
Example 5 | 2-bromo-4-fluorobenzonitrile | 5-d | 93 | 76 |
Example 6 | 4-amino-2-methoxybenzonitrile | 6-d | 88 | 62 |
Example 7 | 4-phenoxybenzonitrile | 7-d | 87 | 65 |
Example 8 | 4-morpholinylbenzonitrile | 8-d | 92 | 74 |
Example 9 | 3-phenoxy-4-methoxybenzonitrile | 9-d | 89/94 | 78 |
Example 10 | Febuxostat | 10-d | 90 | 66 |
。
4-aminobenzoyl cyanides (deuterated 4-aminophenylacetonitrile, 2-d)
1 H NMR(500MHz,Chloroform-d)δ6.94-6.92(m,0.18H,Labelled),6.57-6.55(m,2H),3.62(t,J=1.0Hz,2H),3.16(brs,2H).
4-fluoronitrile (deuterated 4-fluorobenzonitrile, 3-d)
1 H NMR(500MHz,Chloroform-d)δ7.61-7.57(m,0.2H,Labelled),7.15-7.09(m,2H).
3,5-Diaminobenzonitrile (deuterated 3, 5-difluorobenzonitrile, 4-d)
1 H NMR (500MHz, chloroform-d) delta 6.83-6.73 (m, 0.22H, labelled), 5.44 (s, 1H), 4.35 (brs, 4H), 2- (bromomethyl) -4-fluorobenozonile (deuterated 2-bromo-4-fluorobenzonitrile, 5-d)
1 H NMR(500MHz,Chloroform-d)δ7.66-7.58(m,0.07H,Labelled),7.10(d,J=16.5Hz,1H),7.08(m,1H),4.51(d,J=1.1Hz,2H).
4-amino-2-methoxybenzonitril (deuterated 2-bromo-4-fluorobenzonitrile, 6-d)
1 H NMR(500MHz,Chloroform-d)δ7.42-7.40(m,0.13H,Labelled),6.42-6.37(m,2H),4.40(brs,2H),3.92(s,3H).
4-phenoxybenzonitile (deuterated 4-phenoxybenzonitrile, 7-d)
1 H NMR(500MHz,Chloroform-d)δ7.74-7.69(m,0.26H,Labelled),7.37-7.32(m,2H),7.18-7.13(m,2H),7.09(tt,J=9.0,2.0Hz,1H),7.03-7.01(m,2H).
4-morpholino benzazole (deuterated 4-morpholinylbenzonitrile, 8-d)
1 H NMR(500MHz,Chloroform-d)δ7.13-7.07(m,0.16H,Labelled),6.87-6.80(m,2H),3.89-3.83(m,2H),3.19-3.13(m,2H).
3-benzyloxy-4-methoxybenzonitrile (deuterated 3-phenoxy-4-methoxybenzonitrile, 9-d)
1 H NMR(500MHz,Chloroform-d)δ7.45-7.43(m,0.06H,Labelled),7.40-7.37(m,4H),7.35-7.34(m,0.11H,Labelled),7.33-7.29(m,1H),7.26-7.24(m,1H),5.15(t,J=1.0Hz,2H),3.87(s,3H).
2- (3-cyano-4-isobutoxyphenyl) -4-methidazole-5-carboxylic acid (deuterated febuxostat, 10-d)
1 H NMR(500MHz,Chloroform-d)δ8.26(d,J=2.1Hz,1H),8.19-8.17(m,1H),7.22-7.20(m,0.1H,Labelled),3.96(d,J=5.0Hz,2H),2.85-2.77(m,1H),2.68(s,2H),1.15(d,J=7.2Hz,6H)。
The above-described embodiments are only preferred embodiments of the present invention, and are not intended to limit the present invention in any way, and other variations and modifications may be made without departing from the spirit of the invention as set forth in the claims.
Claims (10)
1. A preparation method of a deuterated aromatic nitrile compound is characterized in that an aromatic nitrile compound shown in a formula (I) is used as a raw material, under the protection of inert atmosphere, the aromatic nitrile compound and an aliphatic alcohol compound generate aryl methyl imidic ester in situ in a catalytic system, then the aryl methyl imidic ester and a deuterated reagent generate hydrogen-deuterium exchange reaction, the aryl methyl imidic ester and the deuterated reagent are hydrolyzed in situ to obtain an aromatic nitrile ortho-position deuterated compound, and finally the product is separated and purified; the catalytic system comprises a metal catalyst, an auxiliary agent, an oxidant and a solvent;
2. the method of claim 1, wherein the deuterated reagent is one of deuterium oxide, deuterated methanol and deuterated benzene.
3. The method according to claim 1, wherein the inert gas atmosphere is a gas atmosphere composed of nitrogen or argon.
4. The preparation method according to claim 1, wherein the metal catalyst is selected from one of manganese decacarbonyl, manganese pentacarbonyl bromide, manganese acetate, cobalt hydroxide, ferric oxide and ferroferric oxide.
5. The preparation method according to claim 1, wherein the auxiliary agent is one of sodium acetate, potassium acetate, sodium oxalate, sodium carbonate and potassium carbonate.
6. The method according to claim 1, wherein the solvent is one of N-methylpyrrolidone, tetrahydrofuran, dioxane, cyclohexane, and cyclopentyl methyl ether.
7. The method of claim 1, wherein the oxidizing agent is one of sodium hypochlorite, hydrogen peroxide, peracetic acid, sodium dichromate, sodium perborate, potassium perborate, and methyl hypochlorite.
8. The method according to claim 1, wherein the aliphatic alcohol compound is one of methanol, ethanol, isopropanol, tert-butanol, and benzyl alcohol.
9. The method according to claim 1, wherein the molar ratio of the materials is aromatic nitrile compound: fatty alcohol compounds: oxidizing agent: a deuterated reagent: metal catalyst: auxiliary agent: solvent =1:1.1:1:10-500:0.05-0.20:1:20-500.
10. The method according to claim 1, wherein R is 1 Is one or more of alkyl, alkoxy, vinyl, aromatic substituent, nitro, amido, trifluoromethyl, halogen, pyridine, thiophene and furan; said R is 2 Is one or more of benzyl, methyl, ethyl, isopropyl, tertiary butyl, alkoxy, allyl and tertiary butyl.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210812275.XA CN115215764B (en) | 2022-07-11 | 2022-07-11 | Preparation method of deuterated aromatic nitrile compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210812275.XA CN115215764B (en) | 2022-07-11 | 2022-07-11 | Preparation method of deuterated aromatic nitrile compound |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115215764A true CN115215764A (en) | 2022-10-21 |
CN115215764B CN115215764B (en) | 2023-12-08 |
Family
ID=83612052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210812275.XA Active CN115215764B (en) | 2022-07-11 | 2022-07-11 | Preparation method of deuterated aromatic nitrile compound |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115215764B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0782252A (en) * | 1993-06-30 | 1995-03-28 | Fuji Photo Film Co Ltd | Production of imidic acid ester compound and n-pyrazolylamidoxime compound |
CN104529823A (en) * | 2014-10-23 | 2015-04-22 | 江苏南方农药研究中心 | Benzimidate compound preparation method |
CN108675942A (en) * | 2018-06-19 | 2018-10-19 | 杭州盛漫生物科技有限公司 | A kind of preparation method of aromatic nitrile compounds |
US20220024925A1 (en) * | 2020-07-22 | 2022-01-27 | Acurx Pharmaceuticals Llc | Deuterium-Substituted 7-Substituted-2-(Benzylamino)-6-Ozopurine Compounds and Uses Thereof |
-
2022
- 2022-07-11 CN CN202210812275.XA patent/CN115215764B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0782252A (en) * | 1993-06-30 | 1995-03-28 | Fuji Photo Film Co Ltd | Production of imidic acid ester compound and n-pyrazolylamidoxime compound |
CN104529823A (en) * | 2014-10-23 | 2015-04-22 | 江苏南方农药研究中心 | Benzimidate compound preparation method |
CN108675942A (en) * | 2018-06-19 | 2018-10-19 | 杭州盛漫生物科技有限公司 | A kind of preparation method of aromatic nitrile compounds |
US20220024925A1 (en) * | 2020-07-22 | 2022-01-27 | Acurx Pharmaceuticals Llc | Deuterium-Substituted 7-Substituted-2-(Benzylamino)-6-Ozopurine Compounds and Uses Thereof |
Non-Patent Citations (2)
Title |
---|
SARA KOPF,ET AL.: "Manganese-catalyzed selective C–H activation and deuteration by means of a catalytic transient directing group strategy", 《CHEM. COMMUN.》 * |
XIAOXU YANG,ET AL.: "Manganese-Catalyzed ortho-C-H Alkenylation of Aromatic N-H Imidates with Alkynes: Versatile Access to Mono-Alkenylated Aromatic Nitriles.", 《ADV. SYNTH. CATAL.》 * |
Also Published As
Publication number | Publication date |
---|---|
CN115215764B (en) | 2023-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Visible light-enabled iron-catalyzed selenocyclization of N-methoxy-2-alkynylbenzamide | |
Abid et al. | Synthesis of trifluoromethyl-imines by solid acid/superacid catalyzed microwave assisted approach | |
Wang et al. | Vanadium catalyzed direct synthesis of imines from amines or alcohols and amines by an aerobic oxidative reaction under mild conditions | |
CN110294704A (en) | A method of it prepares containing single fluoroalkyl vinyl hydrocarbon compound | |
Li et al. | Organocatalytic asymmetric intramolecular [3+ 2] cycloaddition: A straightforward approach to access multiply substituted hexahydrochromeno [4, 3-b] pyrrolidine derivatives in high optical purity | |
Zhu et al. | Utilization of nitriles as the nitrogen source: practical and economical construction of 4-aminopyrimidine and β-enaminonitrile skeletons | |
Ni et al. | A convenient access to allylic triflones with allenes and triflyl chloride in the presence of (EtO) 2P (O) H | |
Zhang et al. | Iron/TEMPO-catalyzed direct aerobic oxidative coupling of methyl-mubstituted N-heteroazaarenes with alcohols | |
CN107118215B (en) | A kind of preparation method for treating breast cancer medicines Rui Boxini intermediate | |
CN112301370B (en) | Electrochemical synthesis method of 1, 3-dimethyl-3-difluoroethyl-2-oxindole compound | |
CN111747858B (en) | Method for constructing C-N bond through insertion reaction of nonmetal-catalyzed sulfur ylide and aromatic amine and application | |
Li et al. | Highly enantio-and diastereoselective synthesis of α-trifluoromethyldihydropyrans using a novel bifunctional piperazine-thiourea catalyst | |
CN115215764A (en) | Preparation method of deuterated aromatic nitrile compound | |
CN106187890B (en) | A method of acridone derivatives are catalyzed and synthesized altogether using palladium-copper | |
JP2009029733A (en) | METHOD FOR PRODUCING alpha,beta-UNSATURATED CARBONYL COMPOUND | |
CN111362795B (en) | Preparation method of substituted butyrate derivatives | |
CN108586375B (en) | Green method for synthesizing 2-substituted benzoxazole compound through biocatalytic oxidative cyclization | |
CN110627723B (en) | Trifluoromethyl pyrazole derivative and application thereof | |
CN110194739B (en) | Cyanoalkyl substituted dihydroisoquinolinone compound and preparation method thereof | |
CN112679521A (en) | Method for synthesizing mild azaspiro tricyclic framework molecule | |
CN113754605A (en) | Nitrogen-containing ligand and preparation method and application thereof | |
CN112500368A (en) | 1,3, 4-thiadiazole derivative and preparation method thereof | |
CN108484504A (en) | A kind of method that bionic catalysis is broken C-N keys in aryl nitrogenous compound | |
CN109833908A (en) | A kind of chirality high price iodine catalyst and its preparation method and application | |
CN109369514A (en) | A kind of synthetic method of six-membered carbon ring derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |